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Abstract 
Background: Although the role of clinical/biological factors associated with mortality has 
already been explored in HIV-infected patients on ART, to date little attention has been given to 
the potential role of social vulnerability. This study aimed to construct an appropriate measure of 
social vulnerability and to evaluate whether this measure is predictive of increased mortality risk 
in ART-treated patients followed up in the ANRS CO8 APROCO-COPILOTE cohort. 
Methods: The cohort enrolled 1,281 patients initiating a protease inhibitor-based regimen in 
1997-1999. Clinical/laboratory data were collected every 4 months. Self-administered 
questionnaires collected psycho-social/behavioural characteristics at enrolment (M0), M4, and 
every 8-12 months thereafter. A Multiple Correspondence Analysis using education, employment 
and housing indicators helped construct a composite indicator measuring social vulnerability. The 
outcome studied was all-cause deaths occurring after M4. The relationship between social 
vulnerability and mortality, after adjustment for other predictors, was studied using a shared-
frailty Cox model, taking into account informative study dropout. 
Results: Over a median [IQR] follow-up of 7.9 [3.0;11.2] years, 121 deaths occurred among 
1,057 eligible patients, corresponding to a mortality rate of [95%CI]=1.64[1.37;1.96]/100 person-
years. Leading causes of death were non-AIDS defining cancers (n=26), AIDS (n=23), and 
cardiovascular diseases (n=12). Social vulnerability (HR[95%CI]=1.2[1.0;1.5]) was associated 
with increased mortality risk, after adjustment for other known behavioural and bio-medical 
predictors. 
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Conclusions: Social vulnerability remains a major mortality predictor in ART-treated patients. A 
real need exists for innovative interventions targeting individuals cumulating several sources of 
social vulnerability, to ensure that social inequalities do not continue to lead to higher mortality.  
 
Running head: Mortality in HIV-infected patients on ART: the role of social 
vulnerability 
 
Introduction 
Enough evidence exists today to show that HIV-related mortality has been greatly reduced since 
the introduction of potent antiretroviral therapy (ART) (1, 2). Indeed, HIV-infected patients who 
are not drug users or coinfected with hepatitis C virus (HCV) now tend to have mortality rates 
similar to those observed in the general population, at least in high-income North American and 
European countries (3-5). Known factors leading to higher HIV-related mortality include delayed 
HIV screening (6, 7), delayed care (8-10), non-adherence to treatment (11, 12), exposure to 
certain antiretroviral agents (13), accelerated aging driven by residual immune activation (14), 
and finally, co-occurrence of other virus/diseases (e.g., hepatitis C) (3, 15). In addition, certain 
lifestyle factors such as smoking, alcohol consumption and drug use may also contribute to 
increase the risk of mortality (16-18). 
Social vulnerability can be regarded more as a structural-level exposure, related to the risk 
environment framework, than as an individual factor (19). It can potentially interfere with patient 
response to ART, through reduced access to the different components of the optimal HIV care 
cascade (HIV screening, referral to HIV care, access to HIV treatment) (20-23).  
Before the arrival of ART, results regarding the impact of socio-economic status on 
mortality of HIV-infected patients were heterogeneous, with some studies outlining no impact 
(24, 25), while others highlighted the opposite (26, 27). The impressive increase in survival rates 
thanks to ART has facilitated increased research into competing risk factors of mortality, 
including unhealthy behaviors (16-18) and low socio-economic status (28, 29). However, some 
heterogeneity still remains in post-ART studies, perhaps due to  major differences in the United 
States’ health system (28, 30) and those in Canada (29) or Western European (31-33) countries, 
or to the fact that different socio-economic indicators, measured at household or regional level, 
were used as predictors of mortality (28, 29, 34). To date, several European studies focusing on 
HIV-positive individuals have found an association between mortality and either education level 
(7, 31, 32) or income (33), but few have tried to measure social vulnerability and instability in a 
more complete manner (35). Socio-economic status and education are important components of 
social vulnerability but they have been rarely combined to create a more complex indicator. 
Although educational level is already known to be a predictor of increased mortality in the 
general population (36, 37), few studies have explored the complexity of the relationship between 
educational level and other socio-economic indicators in HIV-infected patients. Furthermore, 
none has linked such a global indicator of social vulnerability to survival rates. 
We used the 12-year French ANRS CO8 APROCO-COPILOTE cohort follow-up of 
HIV-infected individuals, started on ART in 1997-1999, to develop an original combined 
indicator of social vulnerability, based on different proxies of socioeconomic status measured at 
baseline, and to evaluate whether this indicator, is a significant predictor of mortality, 
independently of other clinical and behavioural predictors. In our study, we decided to exclude 
early mortality (i.e. deaths arising during the first 4 months after ART initiation), which are 
mainly due to pre-existing severe clinical and immunovirological statuses before ART initiation, 
as initial ART exposure could not have prevented this early mortality. 
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Methods 
Study design  
The APROCO-COPILOTE cohort was designed to study the clinical, immunological, virological, 
and socio-behavioural course of HIV disease in HIV-1 infected individuals who started the first 
generation of combined antiretroviral regimens, which included protease inhibitors (PI). Between 
May 1997 and June 1999, patients (n=1,281) were enrolled in the cohort in 47 centres throughout 
France, at their first ART prescription, and clinically followed up every 4 months thereafter until 
the end of the study (month 144, written M144).  
 
Data Collection 
At each follow-up visit, the supervising HIV physician completed a form that included the 
patient’s clinical and laboratory data, including HIV CDC clinical stage defined by the Centers 
for Disease Control and Prevention (CDC) (38), plasma HIV RNA level, CD4+ cell count, 
hemoglobin concentration, aspartate and alanine transaminase (AST, ALT) levels, platelet count, 
serum creatinine level and weight.  
The medical questionnaire at enrolment included additional data about the patient’s HIV 
history: HIV transmission category (intravenous drug use (IDU), sex between men, or other), 
time since HIV diagnosis, exposure to antiretroviral treatment before enrolment in the cohort, 
time since ARV initiation, and coinfection with HCV at M0.  
At M0, M4, and every 8 months thereafter during the first five years of follow-up, and 
then every 12 months thereafter, a self-administered questionnaire collected data on socio-
demographic characteristics including age, gender, having a steady partner or not and indicators 
of social status such as education level, employment status, housing stability and housing 
comfort. These questionnaires also gathered information about patients’ behaviours (adherence to 
ART, tobacco and alcohol consumption) and experience with the disease and its treatment (self-
reported side effects, depressive symptoms).  
 
Participants 
For the present analysis we selected all patients who completed the self-administered 
questionnaire at enrolment (M0) and at least one other self-administered questionnaire or who 
died after the first 4 months of follow-up (n=1,057). The study period targeted the follow-up 
period between M4 and M144, and only visits where a corresponding self-administered 
questionnaire was administered were included in the analysis.   
 
Variables 
The outcome used in this analysis was deaths (from all causes) occurring between M4 and M144 
in the selected patients. The overall mortality rate was computed as the number of deaths 
occurring between M4 and M144 over the number of person-years during the study period. 
A composite continuous indicator of social vulnerability was created using a Multiple 
Correspondence Analysis (MCA), performed on the basis of the following socio-economic binary 
indicators measured at M0: having a high school certificate (yes/no), being employed (yes/no), 
having stable housing (yes/no), and having comfortable housing (yes/no). The composite 
continuous indicator was defined by the first of the two factors (with reversed sign) identified in 
the MCA solution.  
The following eight clinical variables were tested in the multivariate analysis to adjust for 
potential predictors of mortality and confounding effects: AIDS stage; being antiretroviral naive 
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at M0; time since HIV diagnosis; plasma HIV RNA>100,000 copies/mL at M0; poor early 
immune status (CD4 counts/mm3<200 at both M0 and M4); a validated indicator of advanced 
liver fibrosis (defined as FIB-4>3.25 (39), where FIB-4 is an index based on age, AST, ALT and 
platelet count (39, 40)); anaemia (defined as a haemoglobin concentration <12 g/dL for women 
and <13 g/dL for men); a validated indicator of renal impairment based on estimated creatinine 
clearance (ECC), computed using the Cockcroft-Gault formula (with ECC<60 mL/min defining 
moderate/severe renal impairment) (41).  
Furthermore, the following seven self-reported psychosocial and behavioural 
characteristics were measured and tested in the multivariate analysis: presence of depressive 
symptoms (using an indicator based on the validated French version of the Center for 
Epidemiologic Studies Depression Scale (CES-D) scale, and defined as a CES-D score > 17 in 
men and > 23 in women) (42); tobacco smoking (using a binary indicator based on the average 
number of cigarettes smoked daily during the 4 previous weeks (smoking > 20 cigarettes/day));  
average daily alcohol consumption (43) (with the following categories: no consumption, low (≤1 
alcohol units (AU)/day), moderate (1–3 AU/day for women and 1–4 AU/day for men), and 
elevated (>3 AU/day for women and >4 AU/day for men)); regular binge drinking (i.e. drinking 
≥ 5 AU on one occasion, at least once a month); perceived side–effects (using a score based on a 
13-item scale of self-reported symptoms and the discomfort they caused, in accordance with the 
French version of the symptom index developed by Justice et al (44), and described elsewhere 
(45); adherence to ART (using a three-level score (high, moderate and low adherence) based on a 
validated algorithm using the ART doses, both prescribed and those actually taken, during the 
previous 4 days (46), according to the methodology established by the AIDS Clinical Trial Group 
(47)). 
Psychosocial characteristics (having a steady partner, depressive symptoms, tobacco and 
alcohol consumption, adherence to ART, and self-reported symptoms), as well as biological 
characteristics (anaemia, the indicator of liver fibrosis, and the indicator of renal impairment) 
were evaluated at each visit and used as time-varying covariates in the statistical analyses. In the 
case of a missing value for any time-varying covariate, the last available value before the current 
visit was carried forward. All other variables (see Table 2) were used as fixed covariates, 
measured at M0, M1 or M4, as we wished to assess the effect of pre-ART or early clinical-
immunovirological characteristics on mortality. 
 
Statistical methods 
The main characteristics at enrolment were compared between the 1,057 patients selected for this 
study and the 1,281 patients enrolled in the cohort, using Chi-2 tests and nonparametric Wilcoxon 
signed-ranks tests. 
The follow-up period was defined for each patient as the period from M4 until his/her 
dropout from the cohort (i.e. the last follow-up visit with an available completed self-
administered questionnaire) or death. The association between the composite indicator of social 
vulnerability and mortality was assessed after adjustment for all potential predictors and 
confounding factors, using a shared-frailty Cox proportional hazards (PH) model. This model is 
an extension of the standard Cox PH model, able to take into account informative study dropout 
(48). In the shared-frailty Cox model the patients were grouped into clusters according to their 
dropout time, each cluster having a specific baseline hazard ratio (individuals in the same cluster 
shared the same baseline hazard ratio, so that their times of death were correlated). Further details 
about the shared-frailty Cox model are provided in the Appendix. The number of clusters was 
assessed by plotting the cumulative hazard function for death according to three categories 
5 
 
defined by the patients’ dropout time: before M20, between M20 and M60, and after M60 (see 
Figure 1). This allowed us to identify two main patterns, corresponding to two clusters defined by 
a dropout time before or after 60 months, respectively (individuals having their last available self-
administered questionnaire before M60 were more likely to die than the others, due to 
unobserved heterogeneity). As is the case with most self-reported health-related data, the dropout 
time was very likely to be informative, as the sickest patients were more likely to have missing 
data. 
Potential adjustment variables having a liberal significance level of P < 0.20 (Wald test) 
in the univariate analyses were considered eligible for inclusion in the multivariate analysis. A 
backward selection procedure was then used to select adjustment variables in the final 
multivariate model (variables were considered significantly associated with the outcome if P ≤ 
0.05). A likelihood ratio (LR) test (see Appendix) was used to test the shared-frailty Cox PH 
specification versus the standard Cox PH specification in the final multivariate model. Plausible 
interactions were assessed by creating interaction terms and adding them to the main effects 
model to test for their significance. 
Stata/SE 12.1 for Windows (49) software was used for all analyses. 
 
Results  
The main characteristics of the 1,057 patients selected for this study were not significantly 
different from those of the 1,281 patients enrolled in the cohort in terms of gender, age, and 
clinical characteristics at baseline (results not shown). 
The 1,057 patients selected for this analysis had a median (IQR) total follow-up period of 
7.9 (3.0;11.2) years, representing 7,379 person-years (counting from 4 months of follow-up 
onwards). The dropout time (i.e. the maximum follow-up time corresponding to a completed self-
administered questionnaire) was before M20, between M20-M60 and after M60 for, respectively, 
20%, 22% and 58% of the selected patients. 
A total of 147 deaths occurred in the cohort, among which 17 patients had not a 
completed self-administered questionnaire at M0 and 9 deaths occurred during the first 4 months 
of follow-up. The other 121 deaths, occurring between M4 and M144 among the 1,057 selected 
patients, were included in this study, corresponding to an overall mortality rate [95% confidence 
interval (CI)] of 1.64 [1.37;1.96] per 100 person-years from 4 months after ART initiation 
onwards. 
The main causes of death were non-AIDS defining cancers (n=26), AIDS (n=23) and 
cardiovascular diseases (n=12).  The causes of death are described in detail in Table 1.  
The selected patients were mostly males (78%) and their median age at enrolment was 36 years 
[interquartile range (IQR), 32;42]. Of the 1,057, 41% were infected through sex between men, 
and 17% through IDU. A quarter (25%) was born outside of Europe. At M4, 58%, 18%, 4% and 
20% reported, respectively, low, moderate, elevated, and no alcohol consumption. Nineteen 
percent smoked more than 20 cigarettes/day and a third of patients reported depressive 
symptoms.   
With respect to the four binary socio-economic indicators used in the MCA, the 
prevalence of ‘No’ answers was 65%, 41%, 20%, and 14% for, respectively, having a high school 
certificate, being employed, housing stability and housing comfort at M0 (see Table 2). The 
solution with two dimensions was retained in the MCA, explaining 58% of the total variance 
(35.6% and 22.5% for the first and second dimensions, respectively). Eigenvalues were 1.4 and 
0.9 for the first and second dimensions, respectively. The first dimension distinguished ‘Yes’ and 
‘No’ categories, with all ‘No’ categories located close to the negative side of the first axis and all 
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‘Yes’ categories located close to its positive side. Accordingly, the first factor of the MCA can be 
interpreted as a measure of good ‘general’ socio-economic status. We defined an indicator 
measuring ‘social vulnerability’ given by the reversed sign of the first factor, so that higher 
values of the indicator correspond to higher levels of social vulnerability. This composite 
indicator of social vulnerability varied between -2.60 and 1.33, with a median [IQR] of -0.35 [-
0.47;0.51]. The employment item provided the highest contribution to this social vulnerability 
indicator (the corresponding discrimination measures for employment status, housing stability, 
education level and housing comfort were 0.48, 0.34, 0.34 and 0.27, respectively). 
With regard to clinical characteristics, 44% of the selected patients were treatment naive, 
a quarter (25%) had been diagnosed more than 8 years before enrolment in the cohort (i.e. before 
the initiation of a PI-containing therapy), 20% had already experienced progression to AIDS 
before enrolment, 37.6% had a CD4 cell count below 200 cells/mm3, 30.1% had a plasma HIV 
RNA level greater than 100,000 copies/mL and approximately 22% were HCV-coinfected at M0.  
Table 2 shows factors potentially associated with mortality (univariate and multivariate analyses). 
Among the socio-behavioural factors, social vulnerability (as measured by the composite 
indicator), the presence of depressive symptoms and the number of self-reported symptoms 
causing discomfort were all associated with a higher risk of death.  
With respect to clinical correlates eligible for the multivariate model, patients infected 
through sex between men were at lower risk of mortality. Conversely, patients with the following 
characteristics had a significantly higher risk of mortality: HCV coinfection, AIDS at M0 (i.e. 
progression to AIDS before ART initiation), longer delays between HIV diagnosis and ART 
initiation, plasma HIV RNA values over 100,000 copies/mL at enrolment, no increase over 200 
CD4 cell count after initial 4 months of treatment, time-varying anaemia and indication of 
advanced liver fibrosis. 
In our study, no significant association (no main effect and no confounding effect) was 
found in univariate analyses between mortality risk and the following known correlates and 
confounders: gender, time since ARV initiation at M0, renal impairment, having a steady partner, 
regular binge drinking, smoking > 20 cigarettes/day, and adherence to ART. 
In the multivariate analysis (Table 2), higher levels of social vulnerability (HR [95% 
CI]=1.2 [1.0;1.5]) were independently associated with higher mortality risk, after adjustment for 
other significant known correlates as follows: age, AIDS stage at M0, plasma HIV RNA>100,000 
copies/mL at enrolment (HR [95% CI]=1.7 [1.0;2.9]), poor early immune status (CD4 
counts/mm3<200 at both M0 and M4) (HR [95% CI]=2.3 [1.3;4.1]), being antiretroviral naive 
and time since HIV diagnosis, anaemia (HR [95% CI]=2.4 [1.5;3.7]), advanced liver fibrosis 
during follow-up (HR [95% CI]=2.5 [1.5;4.3]) and low alcohol consumption (≤1 AU/day, versus 
no consumption) (HR [95% CI]=0.6 [0.4;1.0]). With regard to the interaction effects, a 
significant relationship between being antiretroviral naive and increased mortality risk was found 
only among patients who had been diagnosed more than 8 years before enrolment in the cohort 
(HR [95% CI]=2.8 [1.4;5.4]). Accordingly, time since diagnosis was an effect modifier for being 
antiretroviral naive at enrolment. Furthermore, the clinical CDC stage at enrolment was an effect 
modifier for age as the association between age and increased mortality risk was significant 
among the patients in stage A or B (HR [95% CI]=1.3 [1.1;1.7]), but not significant among the 
patients in stage C at enrolment. 
The results of the LR test (P<10-3) seemed to favour the shared-frailty Cox PH model 
over the standard Cox PH model, as they provided strong evidence for the existence of  
significant latent patient frailty. 
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Discussion 
This is the first study to explore the effect of social vulnerability on mortality in a French national 
cohort of HIV-infected patients receiving ART. It shows that mortality risk increases by 20% per 
each unit increase of the social vulnerability index, even when taking other known clinical and 
behavioural predictors of mortality into account.  
This study also shows that non-AIDS related cancers are the first cause of mortality today, 
while AIDS-related causes of death (including AIDS-defining cancers) constitute the second 
cause. The burden of co-infection is apparent, as in this cohort – which is representative of 
individuals exposed not only to the first generation of combined ART (i.e., PI-containing 
regimens) but also to suboptimal HBV and HCV care - the third most common cause of death 
was related to HCV or HBV associated complications. As a number of unknown causes of death 
were present in the study, we preferred to focus on overall mortality without any distinction of 
the cause.   
To date, only one study, conducted in the US in the ART era, has shown that HIV-
infected participants meeting the US government’s definition of poverty were more likely to die 
than others. Specifically, it found they were 1.5 times more likely to die (30).  
As our model is adjusted for longer periods since HIV diagnosis, for poor early immune status 
during the first four months of ART and for HIV plasma viral load before starting ART, we can 
presume that the most socially vulnerable patients were also those more likely to have 
encountered difficulties with adherence and to have experienced complications of 
immunosuppression or undiagnosed/untreated co-morbidities over the long term course of ART 
treatment. 
The association between social vulnerability and mortality is even more striking in a 
country like France where access to care is free for anyone (all residents in France are covered by 
health insurance by law; most qualify for state health insurance, which generally reimburses 70% 
of patients’ costs). This association reflects the fact that socially vulnerable individuals have to 
first cope with financial worries before thinking about their health status. It is worth noting that 
such populations tend to use emergency services more than the rest of the HIV-infected 
population (50), this greater utilization being an indicator of missed opportunities for early 
detection of severe comorbidities (given that non-AIDS related cancers are the first cause of 
death) or risk factors for acute fatal events (cardiovascular events were the third most common 
cause of death in this cohort). 
Moreover, social vulnerability is often associated with psychiatric disorders, such as 
depressive symptoms, which were a major predictor of clinical progression in a previous analysis 
on the same cohort (51). It may also be correlated with addictive behaviours which may increase 
the risk of acute non-HIV related mortality (i.e. overdoses, suicides, road accidents, etc.) (52, 53).  
Our results are consistent with other studies which showed that low socio-economic status 
and education are associated with increased mortality in HIV-infected individuals before and 
during the era of potent antiretroviral therapy (16-18, 26-29) and remain valid after adjustment 
for known significant correlates of mortality, as anaemia (56-58) or the indicator of liver fibrosis. 
This confirms recent trends indicating a decrease of HIV-related mortality, but also an increase in 
competing mortality causes related to liver-associated damage or comorbidities (3, 15). One 
Danish study (59) recently tried to disentangle the effects of (i) pre-treatment factors, in particular 
HIV-related risk factors (AIDS-defining diseases and insufficient response to ART),  (ii) 
comorbidities including hepatitis C, and (iii) behaviours (drug and excessive alcohol use), on 
overall mortality. It concluded that in HIV patients with no risk factors, the probability of 
survival was equivalent to that of the general population while the main burden of mortality was 
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attributable to behaviours. However, that study did not take into account the changing pattern of 
predictors over time and factors like social vulnerability. 
AIDS clinical stage at ART initiation remained a major predictor of mortality. The effect 
of clinical stage was so strong that it cancelled out the effect of age, the latter remaining 
significant only in patients who had not experienced progression to AIDS at enrolment. This 
result may be due to the specificity of the enrolled patients in the cohort. 
Finally, we found an association between very low alcohol consumption and reduced 
mortality risk, which is in line with previous results for the same cohort (62), which showed that 
individuals with low alcohol consumption presented higher CD4 cell-counts. We do not know 
whether this association is more a proxy of general healthy habits or just "a French paradox", and 
further investigation in other cohorts is needed to verify this result. It is worth noting that some of 
the most important mortality risk factors, like elevated tobacco or alcohol use, were not 
associated with mortality risk in this study. This was perhaps due to the fact that lifetime 
cumulative exposure to alcohol or tobacco could not be computed, as this was not the original 
objective of the study. We did not find any effect of behavioural changes in elevated alcohol or 
tobacco use during follow-up (data not shown), perhaps because cumulative exposures may 
counterbalance certain possible positive effects of abstinence. 
Our choice to use a shared-frailty Cox PH model specification, able to take into account 
informative study dropout, was justified by the results of the LR test for the existence of latent 
frailty depending on the cluster (dropout time before or after M60). Accordingly, the usual 
interpretation of effects based on the standard Cox PH model specification would not have been 
appropriate.  
Some limitations of the study need to be mentioned. First, our results concern a HIV-
infected population which is not representative of the population initiating ART today. This is 
because a non-negligible proportion of our study population (non-treatment naive patients) had 
been exposed to sub-optimal treatments before ART initiation, which is no longer the case for 
those starting treatment today. This may have resulted in increased mortality rates, although 
being antiretroviral naive was not significantly associated with mortality.  
Furthermore, our study shows that even in the French national context of free access to 
care, social vulnerability still plays a role in the inequality of ART care. Although it is difficult to 
generalize our results to other countries, the impact of social vulnerability may be even stronger 
in countries where access to HIV care is not free for everyone.  
While the use of a fixed baseline measure of social vulnerability may seem to be another 
limitation of the study, in reality it is not for two reasons. First, we recomputed the composite 
indicator at different specific follow-up times but it did not greatly evolve over time (data not 
shown). Second, we aimed to emphasize the importance for HIV clinicians to timely identify 
patients who, by combining several different sources of vulnerability due to their social 
conditions, require more comprehensive care, more frequent follow-up visits and ad hoc social 
interventions in order to obtain better response to ART.  
To conclude, this study underlines the fact that social vulnerability is a major risk factor 
of mortality. Free access to HIV care is not enough to make HIV a chronic condition and ensure 
active ageing of people living with the disease. A real need exists for innovative social 
interventions targeting individuals cumulating several sources of social vulnerability, in order to 
protect their right to health care and to ensure that social inequalities do not continue to be a 
source of higher mortality among them. 
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Table 1. Causes of deaths, the ANRS CO8 APROCO-COPILOTE cohort (M4-M144) 
 
Causes of deaths  n (%)  
Non AIDS-related cancer 26 (21.5) 
AIDS-related  23 (19) 
Unknown 12 (9.9) 
Cardiovascular diseases 12 (9.9) 
Accident/aggression  11 (9.1) 
HCV or HBV 10 (8.3) 
Other infectious and parasitic diseases 7 (5.8) 
Overdose 5 (4.1) 
Suicide 5 (4.1) 
Digestive diseases 4 (3.3) 
Unexplained sudden death 3 (2.5) 
Benign tumours 1 (0.8) 
Respiratory diseases 1 (0.8) 
Endocrine, nutritional and metabolic diseases 1 (0.8) 
Total 121 (100) 
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Table 2. Characteristics of the study population and factors associated with deaths (shared-
frailty Cox proportional hazards model, univariate and multivariate analyses, the ANRS CO8 
APROCO-COPILOTE cohort, M4-M144) 
 
 
N (%) or 
median 
[IQR] at  
time origin§§ 
 
Univariate analyses 
 
Multivariate analysis 
 HR  
[95% CI] 
P-
value 
AHR  
[95% CI] 
P-
value 
Clinical CDC stage at M0 & Age 
    Clinical CDC stage C at M0 
    Age for patients in stage C at M0 
    Age for patients in stage A-B at M0 
 
215 (20.3) 
38 [34;45] 
36 [32;42] 
 
9.0 [1.4;57.7] 
0.7 [0.4;1.0] 
1.0 [0.8;1.2] 
 
0.021 
0.050 
0.973 
 
6.2 [0.8;48.7] 
0.9 [0.6;1.4] 
1.3 [1.1;1.7] 
 
0.082 
0.614 
0.010 
Antiretroviral naive & Time since 
HIV diagnosis at M0 
    Antiretroviral naive & time since 
diagnosis < 8 years at M0 
    Antiretroviral naive & time since 
diagnosis ≥ 8 years at M0 
    Not antiretroviral naive at M0 
 
 
377 (35.7) 
 
83 (7.8) 
 
595 (56.3) 
 
 
0.8 [0.5;1.2] 
 
2.9 [1.7;5.0] 
 
1 
 
 
0.350 
 
0.000 
 
 
 
 
1.0 [0.6;1.7] 
 
2.8 [1.4;5.4] 
 
1 
 
 
0.963 
 
0.003 
 
 
Coinfection with HCV at M0 
    No 
    Yes 
 
779 (73.7) 
231 (21.8) 
 
1 
1.8 [1.2;2.6] 
 
 
0.003 
  
CD4+ cell count/mm3 at M0 & M4 
    ≥ 200 at M0 
    < 200 at M0 and ≥ 200 at M4 (at M1 
if missing) 
    < 200 at M0 and < 200 at M4 (at M1 
if missing) 
 
660 (62.4) 
235 (22.2) 
 
114 (10.8) 
1 
1.2 [0.7;1.9] 
 
3.1 [1.9;4.9] 
 
0.569 
 
0.000 
1 
0.6 [0.3;1.2] 
 
2.3 [1.3;4.1] 
 
0.191 
 
0.006 
Plasma HIV RNA at M0 (copies/mL) 
    ≤ 100,000 
    > 100,000 
 
736 (69.6) 
318 (30.1) 
 
1 
2.2 [1.5;3.2] 
 
 
0.000 
 
1 
1.7 [1.0;2.9] 
 
 
0.032 
Haemoglobin§ (g/dL) 
    ≥ 13(12) for men(women) 
    < 13(12) for men(women) (anemia) 
 
881 (83.3) 
176 (16.6) 
 
1 
2.7 [1.8;4.0] 
 
 
0.000 
 
1 
2.4 [1.5;3.7] 
 
 
0.000 
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Indicator of liver fibrosis FIB-4§ 
    ≤ 3.25  
    > 3.25 (advanced fibrosis) 
 
998 (94.4) 
59 (5.6) 
 
1 
3.1 [2.0;4.9] 
 
 
0.000 
 
1 
2.5 [1.5;4.3] 
 
 
0.000 
HIV transmission category 
    IDU 
    Sex between men 
    Other 
 
181 (17.1) 
438 (41.4) 
438 (41.4) 
 
1.2 [0.8;1.8] 
0.5 [0.3;0.8] 
1 
0.437 
0.003 
  
High school certificate at M0 
    No 
    Yes 
 
686 (64.9) 
352 (33.1) 
 
1 
0.7 [0.5;1.1] 
 
 
0.162 
  
Being employed at M0 
    No 
    Yes 
 
434 (41.1) 
575 (54.4) 
 
1 
0.7 [0.4;0.9] 
 
 
0.043 
  
Stable housing at M0 
    No 
    Yes 
 
217 (20.5) 
840 (79.5) 
 
1 
0.7 [0.4;1.0] 
 
 
0.066 
  
Comfortable housing at M0 
    No 
    Yes 
 
147 (13.9) 
888 (84.0) 
 
1 
0.6 [0.4;1.0] 
 
 
0.056 
  
Social vulnerability indicator at M0 
(from MCA) 
-0.35  
[-0.47;0.51] 
1.3 [1.1;1.6] 0.003 1.2 [1.0;1.5] 0.033 
Depressive symptoms§ 
    No (CES-D ≤ 17(23) for 
men(women)) 
    Yes (CES-D > 17(23) for 
men(women)) 
 
695 (65.7) 
 
356 (33.7) 
 
1 
1.9 [1.3;2.7] 
 
 
0.001 
  
Alcohol consumption§ (AU/day) 
    No consumption 
    Low (≤ 1) 
    Moderate (> 1 and ≤ 4(3) for 
men(women)) 
    Elevated (> 4(3) for men(women)) 
 
212 (20.1) 
614 (58.1) 
188 (17.8) 
 
43 (4.1) 
 
1 
0.4 [0.2;0.6] 
0.6 [0.4;1.0] 
 
0.5 [0.5;1.2] 
 
 
0.000 
0.070 
 
0.118 
 
1 
0.6 [0.4;1.0] 
0.8 [0.4;1.6] 
 
0.7 [0.2;1.8] 
 
 
0.044 
0.628 
 
0.459 
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IQR = interquartile range; (A)HR = (adjusted) hazard ratio; CI = confidence interval; CES-D = Center for 
Epidemiologic Studies Depression scale; HCV = hepatitis C virus; AU = alcohol unit; IDU = injection drug 
use; CDC = Centers for Disease Control and Prevention 
§ Time-varying variable 
§§ The frequencies are reported at M0 for fixed variables, and at the first available visit between M4-M144 for 
time-varying variables 
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Figure 1. Cumulative hazard function for death according to the dropout time (before M20, 
between M20 and M60, after M60), the ANRS CO8 APROCO-COPILOTE cohort (M4-
M144) 
 
0
.0
0
1
.0
0
2
.0
0
3
.0
0
4
.0
0
0 5 10 15
Analysis time (years)
Dropout time before M20 Dropout time M20-M60
Dropout time after M60
Cumulative Hazard for Death
 
19 
 
Appendix  
 
The shared-frailty Cox proportional hazards (PH) model 
 
The conditional hazard function of the model, given the unobserved frailty variable  for the ith 
cluster and the covariate vector  is defined by:  
 
where  is the vector of unknown model coefficients,  is the baseline hazard ratio common 
to all subjects,  is the covariate vector for the jth subject in the ith cluster, and the frailty 
variables  are assumed to be independently Gamma distributed with a mean of 1 and unknown 
variance . The interpretation of regression coefficients  remains the same as in the standard 
Cox PH model, but is conditionally made on the frailty variables  which explicitly account for 
the extra variance associated with unmeasured risk factors. 
A likelihood ratio (LR) test for the variance of the frailty variable (LR test for ) was used 
to compare the shared-frailty Cox PH specification versus the standard Cox PH specification.  
 
